PuSH - Publikationsserver des Helmholtz Zentrums München

Langer, H.T.* ; Gilmore, N.K.* ; Hayden, C.M.T.* ; Roux, J.* ; Bariohay, B.* ; Rouquet, T.* ; Awada, M.* ; Marcotorchino, J.* ; Bournot, L.* ; Nunn, E.* ; Titchenell, P.M.* ; Liskiewicz, D. ; Müller, T.D. ; Anyiam, O.* ; Atherton, P.J.* ; Idris, I.* ; Hentschel, A.* ; Roos, A.* ; Haritonow, N.* ; Norman, K.* ; Müller-Werdan, U.* ; Baar, K.*

Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans.

Cell Rep. Med. 7:102665 (2026)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle. In this work, we present four pre-clinical studies and a proof-of-concept clinical trial that address this issue. We report that in obese mice, GLP-1 medicines predominantly reduce body fat alongside a small but significant decrease in LBM. Among lean tissues, loss of liver mass exceeds change in muscle mass. While absolute muscle mass and strength decrease, relative muscle mass and strength improve, resulting in better running performance. Interestingly, while atrophy is similar during immobilization, GLP-1 medicines have a distinct effect on the muscle proteome compared to calorie restriction. Patients with obesity on GLP-1 medicines improve their body composition without negatively affecting strength. Overall, in middle-aged mice and men, GLP-1 medicines slightly decrease absolute muscle values but positively impact body composition and mobility. The clinical trial is registered on clinicaltrials.gov (NCT05606471).
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Glp-1 ; Atrophy ; Function ; Incretins ; Muscle Loss ; Muscle Mass ; Obesity ; Wasting ; Weight Loss; Protein-synthesis; Semaglutide; Atrophy; Efficiency; Quality
ISSN (print) / ISBN 2666-3791
e-ISSN 2666-3791
Zeitschrift Cell Reports Medicine
Quellenangaben Band: 7, Heft: 3, Seiten: , Artikelnummer: 102665 Supplement: ,
Verlag Elsevier
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)